Chapter 6

Valuation and Scenarios

At $13.02 a share (July 24, 2026) Vital Farms carries a market capitalization near $599 million and — net of $51 million of cash and no debt — an enterprise value around $548 million. That is 9x trailing earnings and under 5x trailing adjusted EBITDA, cheap only if fiscal-2025's $114 million of EBITDA is repeatable. Management guided that same figure to about $5 million for fiscal 2026. The price sits between a cyclical peak and a broken model.

What the market pays

Source: share price and market cap from market data, as reported; net cash is cash, cash equivalents and marketable securities of $51.4 million with no debt at March 29, 2026 [1].

On about 46 million diluted shares, the equity is worth roughly $599 million, and because the balance sheet holds no funded debt the enterprise value is simply that figure less the $51.4 million of cash and securities [2]. The debt-free framing that anchors the value case (Financials and Estimates) is real, but the cushion is thinner and moving faster than a static snapshot shows: cash and securities were $113.4 million at the December 2025 year-end [3] and fell $61.9 million in the first quarter alone — to $51.4 million — as capital spending, working capital and $20 million of buybacks all drew on it while operating cash flow ran to negative $18.6 million [4]. Management expects free cash flow to stay negative this year and to fund it partly by drawing the $60 million credit facility [5]. The safety net still exists; it is being spent.

The earnings the multiple rests on

Sources: FY2023 ($48.3M) and FY2024 ($86.7M) adjusted EBITDA [6]; FY2025 ($114M) and the initial FY2026 guide of $105M–$115M [7]; revised FY2026 guide of $0M–$10M [8].

The trailing 4.8x rests on $114 million — the highest adjusted EBITDA in the company's history and more than double the $48.3 million earned two years earlier, a ramp that coincided with avian-flu-inflated conventional egg prices (Financials and Estimates). The instability of that denominator is not a matter of interpretation: the company's own guidance for the very same metric fell from $105–$115 million in February 2026 to $0–$10 million in May 2026 — roughly a $105 million cut in a single quarter — as about $32 million of oversupply-management cost and stepped-up price investment landed on the year [9] [10]. So the cheap trailing multiple is priced on a level of profit the company no longer expects to earn in the current year.

Forward, the multiples invert. On fiscal-2026 consensus the stock shows a loss, so trailing cheapness gives way to a per-share deficit; on fiscal-2027 consensus the earnings return but the multiple is nearly 30x.

Multiple	Trailing FY2025	FY2026E	FY2027E
P/E	9.0x	n.m. (EPS −$0.42)	29.6x (EPS $0.44)
EV / adjusted EBITDA	4.8x	n.m. (~$5M guided)	~6.4x*
EV / net sales	0.72x	0.70x	0.65x

FY2027E EV/EBITDA applies management's stated "double-digit adjusted EBITDA margin" in 2027 (~10% on ~$850M consensus revenue) [11].

Sources: FY2025 actuals [12]; FY2026 guided adjusted EBITDA and the 2027 margin path [13]; FY2026/FY2027 consensus EPS and revenue from consensus estimates, as reported.

What the price implies

The two ends of that table bracket the whole debate, so the useful question is what level of durable profit the current price actually assumes. Working the enterprise value backwards: at $548 million, a low-double-digit EV/EBITDA multiple typical of a growing packaged-food brand — take 10x as an illustration — implies roughly $55 million of sustainable adjusted EBITDA. That is about half fiscal-2025's $114 million peak and roughly eleven times the $5 million guided for fiscal 2026. At today's price the market is paying neither for the peak nor for the trough; it discounts a partial recovery to something near a 7% EBITDA margin — below the 15% the business reached in fiscal 2025 and well above the 0.6% midpoint guided for this year.

Anchoring instead on fiscal 2027 — the first year management expects a double-digit EBITDA margin — and flexing the margin and exit multiple gives a spread wide enough to hold both the value and the value-trap reads at once:

Scenario	FY2027 adj. EBITDA (margin)	EV/EBITDA	Implied EV	Implied value/share	vs $13.02
Bear	~$40M (5% on ~$800M)	6x	~$240M	~$6	−52%
Base	~$85M (10% on ~$850M)	8x	~$680M	~$16	+22%
Bull	~$117M (13% on ~$900M)	11x	~$1.29B	~$29	+123%

Source: illustrative scenarios derived from management's FY2027 double-digit-EBITDA-margin target and 2030 model [14] [15]; each adds $51M net cash on ~46M shares. Not forecasts.

The base case ties to management's own recovery arithmetic: at roughly $85 million of fiscal-2027 EBITDA, today's enterprise value is about 6.4x that figure — undemanding if the recovery lands. The bull case leans on the December 2025 Investor Day target of $2 billion of revenue at a 15–17% adjusted EBITDA margin by 2030 [16], a bar the company itself raised even as it cut the near term — a $1 billion / 2027 goal became a $2 billion / 2030 goal [17]. The bear case needs no catastrophe, only for the recovery to arrive later and shallower than planned.

The sell-side prices a tighter, nearer band. The mean and median analyst target is $12.00 — slightly below the $13.02 quote — inside a $10 to $16 range, and the rating mix has moved to 1 strong buy, 2 buy and 7 hold; three months earlier eight of twelve ratings were buys. The downgrade cluster mirrors the guidance cut. Those are twelve-month targets, which is why they sit near the current price rather than reaching for the multi-year model.

Source: analyst price targets, ratings and consensus revisions from consensus estimates, as reported.

Bull and bear on the same facts

The case is genuinely two-sided because the same facts read two ways. The report's prior chapters supply both columns.

Shared fact	Bull reading	Bear reading
Debt-free, $51M net cash	Trough is survivable without financing; room to buy back stock	Cushion fell $62M in a quarter; FCF negative, revolver now contemplated
FY2025 adj. EBITDA $114M, 15% margin	Proven earning power to re-attain on an existing plant	Guided to ~$5M for FY2026; the peak was flattered by inflated egg prices
Pasture-raised volume +27% CAGR; VITL the leader	Durable secular tailwind; only 10.5% household penetration	Disclosed share fell from over 90% to over 54% then vanished from the filing
Retention intact; distribution 145→170–175 points	Brand moat holds; only new-trial is cyclical	Trial is half of growth and is exactly what stalled; it is price-gap dependent
Recovery bridge fully named (30% GM exit-2026)	Specific, quantified levers; insiders buying at $8–$18	Assumes a retail price floor VITL does not set; farmer-cost tail runs past 2027
Trailing 9x P/E, 4.8x EV/EBITDA	Cheap for a growing branded business	Multiples meaningless on a cyclical-peak denominator

Sources: derived from the report's prior chapters — Financials and Estimates, Category and Moat, Unit Economics and Ownership and Incentives — and their cited filings; the FY2026 guidance cut and recovery bridge [18].

Where this leaves the read

At $13.02 the price already discounts a deep trough: it values the business at roughly half of fiscal-2025's earning power and about 6x a fiscal-2027 recovery that both management and consensus expect. Set against a brand whose existing-customer base held through the shock, a category still growing double digits by volume, and a balance sheet with no debt, the risk and reward skew modestly to the upside — provided the double-digit-EBITDA-margin recovery lands within about a year of the fiscal-2027 schedule. The evidence for that is the fixed-cost leverage in an owned plant already sized for more than $1 billion of revenue, and management and directors staking their pay and personal cash on the same 2027 outcome (Ownership and Incentives).

The strongest fact against it is the one this chapter opened on: the company's own EBITDA guidance for the current year fell by roughly $105 million in a single quarter, and the recovery bridge explicitly assumes outdoor-access egg prices hold at current levels [19]. The denominator under the cheap multiple is unstable, and a second leg down in premium egg prices would push the recovery out and keep free cash flow — and the cash cushion — draining. What would change the read is concrete: gross margin failing to track back toward the 30% exit rate management set for late fiscal 2026, or a further cut to the EBITDA path at the next print. Either would move the base case toward the bear column, and the price with it.